Invatin Technologies

Company Overview

Snapshot

Founded in March 2016 by Dr. Udi Nussinovitch, Invatin Technologies operates with 1–10 employees. The company secured seed funding in August 2018, with G.O Innovation participating in the round. Invatin Technologies ceased operations in March 2022.

Business overview

Invatin Technologies develops medical devices within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics. The company's core product, SYNAXIS-XT, is an aortic arch uni-axial diverter designed to provide embolic protection to the arteries ascending from the aortic arch, thereby minimizing the risk of cerebral ischemic stroke. This technology aims to prevent stroke in high-risk patients by redirecting emboli away from the brain while preserving blood flow patterns. Invatin Technologies serves the healthcare market, targeting providers and patients with its cardiology-focused solutions.

Company Intelligence Q&A

What is Invatin Technologies' primary product?

Invatin Technologies' primary product is SYNAXIS-XT, an aortic arch uni-axial diverter designed to deliver embolic protection to the three arteries ascending from the aortic arch, minimizing the risk for cerebral ischemic stroke.

When was Invatin Technologies founded?

Invatin Technologies was founded in March 2016.

Who is a key founder of Invatin Technologies?

Dr. Udi Nussinovitch is a founder and CSO of Invatin Technologies.

What is the status of Invatin Technologies?

Invatin Technologies is currently non-active and ceased to operate in March 2022.

What type of funding did Invatin Technologies receive?

Invatin Technologies received seed funding in August 2018, with G.O Innovation participating as an investor.